Results 251 to 260 of about 89,537 (296)
Cancers, 2020 Myelofibrosis (MF) is a myeloproliferative neoplasm hallmarked by the upregulation of the Janus kinase (JAK)—signal transducer and activator of transcription (STAT) pathway with associated extramedullary hematopoiesis and a high burden of disease ...
Andrew T Kuykendall +2 more
exaly +2 more sources
Cancer Cell, 2015 SummaryAlthough clinically tested JAK inhibitors reduce splenomegaly and systemic symptoms, molecular responses are not observed in most myeloproliferative neoplasm (MPN) patients. We previously demonstrated that MPN cells become persistent to type I JAK
Sara C Meyer +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Current Medicinal Chemistry, 2019
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Musumeci, Francesca +7 more
openaire +3 more sources
Janus kinases (JAKs) are a family of non-receptor tyrosine kinases, composed by four members, JAK1, JAK2, JAK3 and TYK2. JAKs are involved in different inflammatory and autoimmune diseases, as well as in malignancies, through the activation of the JAK/STAT signalling pathway.
Musumeci, Francesca +7 more
openaire +3 more sources
JAK inhibitors for rheumatoid arthritis
Expert Opinion on Investigational Drugs, 2023JAK (Janus kinase) is a type of non-receptor tyrosine kinase that includes JAK1, JAK2, JAK3, and Tyk2. Currently, there are five JAK inhibitors approved for treating rheumatoid arthritis. These inhibitors vary in their selectivity for different JAK isoforms.This review outlines the mode of actions and the results of Phase III trials of the JAK ...
Satoshi Kubo +2 more
openaire +2 more sources
Future Medicinal Chemistry, 2014
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock +3 more
openaire +2 more sources
Consisting of four members, JAK1, JAK2, JAK3 and TYK2, the JAK kinases have emerged as important targets for proliferative and immune-inflammatory disorders. Recent progress in the discovery of selective inhibitors has been significant, with selective compounds now reported for each isoform.
Brian W, Dymock +3 more
openaire +2 more sources
JAK inhibitors and black box warnings: what is the future for JAK inhibitors?
Expert Review of Clinical Immunology, 2023Janus kinase inhibitors (JAKi) have dramatically improved the treatment of various autoimmune and myeloproliferative disorders. Recently, concern has arisen regarding their safety in patients with rheumatoid arthritis.Here, we provide a comprehensive summary of the major current and emerging JAKi and their indications, address recent studies on ...
Kate Tokareva +7 more
openaire +2 more sources
JAK Inhibitors in the Treatment of Lichen Planopilaris
Skin Appendage Disorders, 2023<b><i>Background:</i></b> Lichen planopilaris (LPP) is an autoimmune disorder leading to lymphocytic cicatricial alopecia. Different agents such as hydroxychloroquine, methotrexate, cyclosporine, and mycophenolate mofetil have been tried to control hair loss with limited efficacy. JAK inhibitors are immune-modulating drugs which
Maryam, Nasimi, Mahshid Sadat, Ansari
openaire +2 more sources
JAK Inhibitor in CALR-Mutant Myelofibrosis
New England Journal of Medicine, 2014na
PASSAMONTI, FRANCESCO +2 more
openaire +6 more sources